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tic drug paclitaxel (50 nM) chosen for this study caused less then 30% 
death of 3LL cancer cells in vitro, was not toxic to DC and stimulated 
DC maturation and function in vitro. First, we found that 3LL cells 
inhibited DC maturation and function in vitro and immunosuppressive 
effect of 3LL cells was signiﬁcantly decreased after their pretreat-
ment with paclitaxel. Next, we investigated a combination of low dose 
chemotherapy and DC vaccine in vivo using s.c. Lewis lung carcinoma 
model. Animals were divided into four groups: (1) non-treated, (2) 
treated with intraperitonel injection of paclitaxel 9 days after tumor in-
oculation, (3) treated with intratumoral injection of immature DC, and 
(4) intraperitoneal injection of paclitaxel followed by intratumoral DC 
injection. We observed a signiﬁcant decrease in tumor growth in-group 
4 associated with CD4 and CD8 T cells inﬁltration of tumor and IFN-γ 
production by lymph node cells. Using microdialisis technique for mea-
suring cytokines, chemokines, and growth factors released within the 
tumor bed in dynamics in live freely moving animals, we determined 
whether the combination therapy alters immunological network at the 
tumor site. Our results demonstrated that the combination of low-dose 
paclitaxel and DC vaccine resulted in increase in intratumoral MCP-1, 
IP-10, and KC chemokines and decrease in intratumoral IL-1α. 
Novel Therapeutics: New Horizon and Others
P3-037 NT: New Horizon and Others Posters, Wed, Sept 5 – Thur, Sept 6 
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Objectives: Lymphatic metastasis is a critical prognostic factor for 
lung cancer. Delivering therapeutic agent to the lymphatic system poses 
a signiﬁcant challenge. The objective of the study is to develop a target-
ed drug delivery system to control lymphatic metastasis in lung cancer. 
Methods: Paclitaxel (PTX) loaded Poly(lactide-co-glycolide) micro-
spheres (PLGA-PTX) were constructed using a spray drying technique. 
The microspheres were incorporated into gelatin sponge to form an 
implantable device. The morphology, particle size and drug releasing 
properties of the system were characterized in vitro. Cytotoxicity of 
PLGA-PTX to the H460 human lung cancer cells was examined by clo-
nogenic assay. The pharmacokinetics was studied in Sprague Dawley 
rats with either of the following four regimens (1) PTX 8 mg/kg given 
i.v.; (2) PTX 8 mg/kg given intrapleurally (ipl.); (3) PLGA-PTX (100 
mg/kg) given intrapleurally; (4) gelatin sponge containing PLGA-PTX 
(100 mg/kg) implanted intrapleurally. The dwell time of the chemo-
therapy was 1h, 3h, 8h, 12h, 24h, 48h, 7d, for the former two regimens 
and 12h, 24h, 3d, 7d, 14d, 21d, 28d for the latter two regimens. PTX 
concentrations in lymph node and plasma were determined by LC/MS. 
The area under the concentration vs time curve (AUC) was calculated. 
Therapeutic efﬁcacy was assessed in a nude rats H460 orthotopic lung 
cancer model with 100% incidence of lymphatic metastasis. Fourteen 
days following endobronchial tumor implantation, the lung tumors 
were resected by pneumonectomy. Animals were treated intraopera-
tively with either ipl. implantation of gelatin sponge containing PLGA-
PTX (100 mg/kg), placebo sponge or no treatment (n=10/group). 
Tumor recurrences were examined 32 days later. 
Results: The microspheres had a mean particle size of 3.5 ± 2.1 μm, a 
drug loading of 7.0% (w/w). The system exhibited controlled release 
properties in vitro. PTX and PTX extracted from PLGA-PTX exhib-
ited similar cytotoxic effect on the colony formation of H460 cells. 
The AUC for lymph node was signiﬁcantly higher with ipl. admin-
istration of PLGA-PTX and gelatin sponge containing PLGA-PTX 
(6904.3±245.5 and 6470.3±366.3 μg-d/g respectively) as compare to 
i.v. and ipl. administration of free PTX (10.52±0.27 and 31.47±1.09 
μg-d/g respectively). This represents more than a 6000-fold increase in 
drug exposure for lymphatic tissue after ipl. administration of PLGA-
PTX. Conversely, the AUC of the plasma was lower with PLGA-PTX 
administration as compare to free PTX administration. Lymph node tu-
mor was found in 20% of the treatment group vs 100% of the non-treat-
ment and the placebo controls (p<0.01). In the drug treatment group 
the weight of metastatic lymph nodes was signiﬁcantly lower than that 
of non-treatment and placebo controls. PLGA-PTX microspheres were 
microscopically identiﬁable in the targeted lymph nodes. 
Conclusions: The system combines controlled release properties of 
PLGA-PTX with structural advantages of gelatin matrix. PLGA-PTX 
inhibits lung cancer cell growth in vitro and reduces lymphatic metasta-
sis in vivo. These effects may be attributable to the improved pharma-
cokinetic distribution of PTX to the lymphatic system. 
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Background: Photodynamic therapy (PDT) is a novel method for treat-
ment of malignancy. It is effective method for palliation of lung cancer 
and can improve results of combined treatment. Therapeutical improve-
ment in this ﬁeld may result from use of new photosensitizers. The aim 
of this study is to estimate direct results of photodynamic therapy with 
chlorine photosensitizers on the central lung cancer. 
Methods: The photodynamic therapy with chlorine photosensitizers 
(Photolon, Photoditazin) on 41 patients with central lung cancer is 
carried out. 37 males, 4 females, aged 42-81 years (mean 61.5) with 
advanced inoperable bronchogenic cancer and endobronchial luminal 
obstruction were studied. Most patients were at the stage IIIb-IV. The 
histology of the tumors was: non small cell in 36 and small cell in 5 
patients. The pre/post-treatment protocol consisted of: clinical, radio-
logical and bronchoscopic examination, pulmonary function testing. 
Intravenous injection of chlorine photosensitizers (1.5-2.4 mg/kg body 
weight) was given, 2-3 h later the tumor was illuminated with 662 nm 
laser light. We use a ﬂexible ﬁbreoptic bronchoscope for visualiza-
tion and placement of the optical ﬁbre, which was passed through the 
biopsy channel of the instrument to the target tissue. For 3 days after 
the procedure the patients were under special light conditions. PDT 
repeated if necessary.
Results: Positive radiological dynamics in the form of the sanction 
atelektasis elimination of ventilating infringements was observed in 
66,7 % cases. In a month after the PDT bronchoscopy was done (37 
patients) complete response was observed in 23 (62.2 %) cases, partial 
response in 12 (34.4%), in 2 patients reductions of a tumor is not 
revealed. Vital capacity (VC) after PDT increase from 3 % up to 33% 
(mean 20 %). Reduction of cough was noted in 31 (77.5 %) of 40 pa-
tients. Reduction of dyspnoea was noted in 65.8 % patients. Haemoph-
